Early and long-term outcomes of argatroban use in patients with acute noncardioembolic stroke

Efficacy and safety of Argatroban in patients with acute ischemic stroke: a systematic review and meta-analysis

“…The included studies were from different countries: eight from China ( 11–16 , 19 , 22 ), two from Japan ( 18 , 21 ), one from Korea ( 17 ), two from the USA ( 20 , 23 , 24 ) and one from the UK ( 20 ). Among the included studies, six studies were RCTs ( 11 , 14 , 16 , 20 , 22 , 24 ) and eight studies were observational studies ( 12 , 13 , 15 , 17–19 , 21 , 23 ). In the intervention group, four studies adopted Argatroban alone ( 16 , 18 , 21 , 24 ), six studies adopted Argatroban combined with MAPT or DAPT ( 12–15 , 19 , 22 ), three studies adopted Argatroban combined with alteplase ( 11 , 20 , 23 ) and one study adopted Argatroban combined with MT ( 17 ).…”

“…The quality evaluation of included observational studies was presented in Table 3 . The eight observational studies scores seven or more stars and are also with high quality ( 12 , 13 , 15 , 17–19 , 21 , 23 ).…”

“…We chose mRS score of 0–1 and mRS score of 0–2 at 90 days to evaluate the good functional outcome after stroke. Five studies reported the rate of mRS score of 0–1 ( 11 , 12 , 14 , 20 , 22 ) and mRS score of 0–2 at 90 days ( 11 , 15 , 17 , 22 , 24 ), respectively. The rates of mRS score of 0–1 (OR = 1.38, 95% CI: 0.71–2.67, I 2 = 77.56%) and mRS score of 0–2 (OR = 1.18, 95% CI: 0.98–1.42, I 2 = 0.00%) at 90 days did not significantly improve in the Argatroban group compared with the control group ( Figure 3 ).…”

“…In this study, adverse events included ICH, major extracranial bleeding and mortality. A total of 12 studies reported the rate of ICH ( 11–15 , 17–20 , 22 , 23 ), 10 studies reported the rate of major extracranial bleeding ( 11–18 , 20 , 24 ) and 7 studies reported the rate of mortality ( 14 , 15 , 17 , 20 , 21 , 23 , 24 ). As shown in Figure 4 , the adverse event rates of Argatroban group were no significantly different from that of the control group (ICH: OR = 1.02, 95% CI: 0.68–1.51, I 2 = 0.00%; major extracranial bleeding: OR = 1.22, 95% CI: 1.01–1.48, I 2 = 0.00%; mortality: OR = 1.16, 95% CI: 0.84–1.59, I 2 = 0.00%).…”

Corticospinal Tract Hypoperfusion Associated With Unexplained Early Neurological Deterioration After Intravenous Thrombolysis

“…In addition, the ARAIS trial has been conducted to evaluate whether argatroban plus rt-PA is superior to rt-PA alone in improving functional outcomes in patients with AIS ( 18 ). A recent study indicated that argatroban reduced the risk of END in AIS after reperfusion therapy ( 19 ). Thus, CST hypoperfusion might be a potential indication to explore whether argatroban plus rt-PA could reduce unexplained END.…”